Skip to main content

FDA committee votes against Eli Lilly cancer treatment over concerns trials conducted only in China

FDA committee members said the trial population of mostly Asian men did not represent the diversity of U.S. patients.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.